The acquisition of HSO Health Care GmbH cements Chr. Hansen’s long-term commitment to its probiotics business, and the fast-growing category for women’s health, where scientifically proven probiotic solutions are becoming increasingly popular among consumers
Chr. Hansen Holding A/S and HSO Health Care GmbH today entered into an agreement, under which Chr. Hansen will acquire HSO Health Care. Th
Up to one in four infants globally suffer from excessive crying and fussing – often called colic. A new study shows that the BB-12® probiotic strain may help reduce crying duration and the number of crying episodes and bring relief to infants and their parents
Innovationsfonden har ydet en bevilling til Chr. Hansen, Københavns Universitet og Dansk Teknologisk Institut (DTI), som sammen vil arbejde på at udvikle naturlige løsninger til en bæredygtig landbrugsproduktion
The Danish Innovation Fund has awarded a grant to Chr. Hansen, University of Copenhagen and the Danish Technological Institute (DTI) who will join forces to develop natural solutions for sustainable agricultural production
Chr. Hansen and FMC Corporation have announced a five-year extension of their collaboration to develop and commercialize natural solutions for the agricultural industry
Clinical trial demonstrates that probiotic strain strengthens the defense against gut damage caused by regular use of household painkiller
Prota Therapeutics, the developer of oral immunotherapies to treat food allergies, has partnered with Chr. Hansen. The partnership will assess the world’s best documented probiotic strain, LGG®, in a Phase III clinical trial to develop a treatment for peanut allergy.
- Delivering on operational and strategic priorities while continuing to build long-term growth
Research on the human microbiome has exploded in recent years revealing it to be of major importance for human health and disease, creating opportunities for development of next generation probiotics. That is why Chr. Hansen is proud to announce that we have now expanded our world class strain library of potential microbiome modulating strains.
Research confirming the effective in vitro inhibition of the growth of E. coli will be showcased at the Congress on Gastrointestinal Function, where other central studies with livestock and poultry species for food production and biomedical research, as well as clinical and nutritional studies relevant to improving human health and well-being will be presented.
New research confirms hatch-to-market benefits of probiotics in poultry production.
Natural solutions that advance human health are in high demand and the expected growth for microbial solutions in this industry is 7-9%. Chr. Hansen is the world’s leading supplier of probiotics to dietary supplements, infant formula and dairy, and through the acquisition of the LGG® business, the company is now further strengthening its microbial platform across all three categories.
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.
